Harnessing Biomaterials to Overcome Challenges in Cancer Immunotherapy:

Vivek Pazhamalai Vels Institute of Science, Technology and Advanced Studies, Chennai, India https://orcid.org/0000-0003-2088-7545 Meenupriya Venkatesan Vels Institute of Science, Technology and Advanced Studies, Chennai, India Jayasri Rajkumar Vels Institute of Science, Technology and Advanced Studies, Chennai, India S. S. Meenambiga Vels Institute of Science, Technology and Advanced Studies, Chennai, India https://orcid.org/0000-0002-5445-525X S. Ivo Romauld Vels Institute of Science, Technology and Advanced Studies, Chennai, India https://orcid.org/0000-0003-0610-0646 K. Rajakumari Vels Institute of Science, Technology and Advanced Studies, Chennai, India https://orcid.org/0000-0002-8102-9512 V. Gowthami Vels Institute of Science, Technology and Advanced Studies, Chennai, India Harnessing Biomaterials to Overcome Challenges in Cancer Immunotherapy

The intrinsic immune system activity awakens and trains the patient's immune system to destroy tumor cells. Immunotherapy has become a standard method for treating cancer since it is a more potent and secure option than conventional therapies like surgery, radiotherapy, and chemotherapy. Chimeric antigen receptor-modified T cells, immune checkpoint blockades, and cancer vaccines are the three primary forms of cancer immunotherapy that have been developed recently. Chemotherapy, radiation therapy, and surgery continue to be the mainstays of cancer treatment despite decades of advancements. Lung cancer, melanoma, advanced bladder, kidney, and other advanced tumors have all been successfully treated with immunotherapy. Immunotherapy is used to cure illnesses by regulating an overactive or underactive immune system. Biomaterials efficiency will be increased with the help of immune system engineering and targeted drug delivery. Chapter highlights the recent advancement in tailored biomaterials for cancer immunotherapy.
chapter 6 2025 4 25 219 252 10.4018/979-8-3373-1305-4.ch006 20250613013425 https://services.igi-global.com/resolvedoi/resolve.aspx?doi=10.4018/979-8-3373-1305-4.ch006 https://www.igi-global.com/viewtitle.aspx?TitleId=377587 10.1126/scitranslmed.aam8645 10.3390/medicina56010015 10.3389/frlct.2024.1487377 10.1016/j.tice.2021.101553 10.6004/jnccn.2010.0067 10.1038/s41416-018-0328-y 10.1007/978-3-319-41129-3_3 Bhatia, S., & Bhatia, S. (2016). Natural polymers vs synthetic polymer. Natural polymer drug delivery systems: nanoparticles, plants, and algae, 95-118 10.1002/mds3.10069 10.1016/j.matpr.2020.01.437 10.3390/pharmaceutics14020288 10.1002/admi.202000819 10.1002/mco2.8 10.1002/mco2.8 10.3389/fgene.2021.785153 10.3390/ijms10041514 10.1002/adfm.201902785 10.1038/s44222-022-00004-6 10.3390/pr11092696 10.1016/j.biomaterials.2020.119827 10.1016/j.lungcan.2008.03.016 10.1039/C9CS00271E 10.1016/j.addr.2024.115306 10.3390/cancers11050628 10.1039/D4CS00636D 10.1089/jir.2018.0019 10.1016/j.coi.2015.12.003 10.1063/5.0125692 10.1016/j.biopha.2023.115048 10.1016/j.biopha.2023.115048 10.1002/EXP.20210157 10.1007/s00170-022-08770-8 10.1016/j.cytogfr.2020.07.001 10.3390/polym13071027 10.3389/fimmu.2017.00829 10.1089/cbr.2010.0902 10.3389/fimmu.2019.02965 10.1016/j.biomaterials.2019.119659 10.1136/jitc-2024-009063 10.1002/advs.202200756 10.3747/co.27.5223 10.1002/adfm.201802540 10.1098/rsif.2007.0218 10.4161/onci.19549 10.18632/oncotarget.7304 10.18632/oncotarget.7304 10.1016/j.polymdegradstab.2017.08.024 Collagenous extracellular matrix biomaterials for tissue engineering: Lessons from the common sea urchin tissue. K. L.Goh 2017 10.3390/ijms18050901 901 5 International Journal of Molecular Sciences GohK. L.HolmesD. F. (2017). Collagenous extracellular matrix biomaterials for tissue engineering: Lessons from the common sea urchin tissue.International Journal of Molecular Sciences, 18(5), 901. 18 10.3390/polym14163430 Ressler, A. (2022). Chitosan-based biomaterials for bone tissue engineering applications: a short review 10.1038/s41568-019-0186-9 10.1186/s13045-020-00922-1 10.1634/theoncologist.2012-0123 10.1016/j.nantod.2019.04.005 10.1515/ntrev-2020-0027 Natural products: A minefield of biomaterials. O. O.Ige 2012 1 International Scholarly Research Notices IgeO. O.UmoruL. E.AriboS. (2012). Natural products: A minefield of biomaterials.International Scholarly Research Notices, 2012(1), 983062. 2012 10.3389/fimmu.2022.1012806 10.1016/j.mtcomm.2022.104068 10.3390/cells12172159 10.3390/vaccines11020458 10.1211/jpp.59.4.0001 10.1186/s13048-024-01507-z 10.3390/cancers15102721 10.1016/j.dyepig.2021.109766 10.1016/j.actbio.2019.02.016 10.1038/471561a 10.3390/cancers3043856 10.3390/ijerph17196938 10.3389/fbioe.2020.612950 10.2147/IJN.S480799 10.1016/j.carbpol.2022.119452 10.1039/D3NR05768B 10.4172/2155-9929.1000350 10.3390/polym3031377 10.1016/j.ccell.2015.03.007 10.1021/acs.jpcc.4c04847 10.1007/978-981-15-8640-8 10.1038/nrd.2017.243 10.1038/nrc3239 10.1016/j.drudis.2012.05.010 10.7759/cureus.71694 10.1201/9780429399039-2 Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2020). Nanocarriers as an emerging platform for cancer therapy. Nano-enabled medical applications, 61-91. 10.1039/D2CS00352J 10.1007/s13346-023-01405-9 10.3390/cancers14163972 10.1007/978-3-030-21614-6_1 Radhakrishnan, S., Nagarajan, S., Bechelany, M., & Kalkura, S. N. (2020). Collagen based biomaterials for tissue engineering applications: A review. Processes and phenomena on the boundary between biogenic and Abiogenic nature, 3-22 10.5455/2319-2003.ijbcp000812 10.1126/science.aar4060 10.1038/s41467-020-17670-y 10.3390/ijms20040840 10.1038/nrc2355 10.1038/s41568-019-0224-7 Nanotechnology-based products for cancer immunotherapy. F.Shams 2022 1 Molecular Biology Reports ShamsF.GolchinA.AzariA.Mohammadi AmirabadL.ZareinF.KhosraviA.ArdeshirylajimiA. (2022). Nanotechnology-based products for cancer immunotherapy.Molecular Biology Reports, •••, 1–24.34716502 ••• 10.1016/j.cell.2015.03.030 10.3390/ijms19051389 10.3390/curroncol29050247 10.3322/caac.21551 10.1016/j.jconrel.2011.06.008 10.1016/j.progpolymsci.2011.05.003 10.1007/978-1-4684-5523-6_2 10.1016/j.biomaterials.2017.09.017 10.4049/jimmunol.1401109 10.1016/j.biopha.2020.109821 10.1016/j.pharmthera.2016.05.004 Engineering tolerance using biomaterials to target and control antigen presenting cells. L. H.Tostanoski 2016 403 117 Discovery Medicine TostanoskiL. H.GosselinE. A.JewellC. M. (2016). Engineering tolerance using biomaterials to target and control antigen presenting cells.Discovery Medicine, 21(117), 403–410.27355336 21 10.1016/j.ejcsup.2013.07.009 10.1021/cr940351u 10.1007/978-3-030-80962-1_343-1 10.3390/vaccines11121783 10.1002/adhm.201900679 10.3390/ijms25021180 10.1158/1078-0432.CCR-16-0049 10.1158/1078-0432.CCR-07-1157 10.1186/s40824-023-00369-8 10.1016/j.nantod.2021.101225 10.1002/ange.202002780 10.20892/j.issn.2095-3941.2018.0493 10.1038/s41401-020-0372-z 10.1038/s41392-024-01868-3 Cancer epidemiology and prevention. K. Y.Yoo 2003 1 1 Epidemiology and Health YooK. Y.ShinH. R. (2003). Cancer epidemiology and prevention.Epidemiology and Health, 25(1), 1–15.11850580 25 10.34133/bmr.0045 Yu, G., Ye, Z., Yuan, Y., Wang, X., Li, T., Wang, Y., ... & Yan, J. (2024). Recent Advancements in Biomaterials for Chimeric Antigen Receptor T Cell Immunotherapy. Biomaterials Research, 28, 0045 10.1016/j.jconrel.2024.09.008 10.3389/fimmu.2021.721830 10.1016/j.jconrel.2018.10.008 10.1038/s41423-020-0488-6